Centene (CNC) Stock May Be Cheap Following Raised 2026 Outlook
Centene stock has more than doubled over the past year, yet the valuation checks still lean on the cheap side, which raises a clear question about how much of the recent optimism is already in the price.
- Centene has returned 154.2% over the past year, which puts recent shareholders in a strong position and makes the current price level far more important for anyone considering new capital.
- Stronger profit and an improved outlook have supported sentiment, while slower than expected Medicaid margin recovery may limit how much investors are willing to pay for that story.
- On Simply Wall St's broader checks, Centene screens as undervalued in 5 of 6 valuation tests, which suggests the current market price still embeds relatively conservative assumptions.
The issue now is whether Centene's share price already reflects the good news on profits and outlook, or if the valuation still leaves room for further upside.
Does Centene Look Undervalued on Sales?
P/S is a useful lens for Centene because revenue is the key driver for an insurer that runs large membership books and operates on relatively tight margins.
Centene trades on a P/S ratio of about 0.2x, compared with a Healthcare industry average of 1.4x and a peer average near 1.9x. The fair ratio implied by Simply Wall St's model is 0.9x, which already factors in the company’s size, business mix and risk profile. This still sits well above where the stock trades today.
Despite the recent upgrade to Centene’s 2026 outlook, the very low P/S multiple suggests the market is still pricing the stock at a sizeable discount to both sector norms and the model’s fair ratio. That is consistent with the broader valuation checks that point to relatively conservative expectations baked into the current price.
On the P/S multiple, Centene stock currently screens as undervalued compared with both its fair ratio and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Centene Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Centene valuation puzzle leaves off and explain what would need to happen to Centene's future growth, margins and earnings for the stock to be worth materially more or less than today's price on the Community page. Each one sets out a clear, testable view of Centene's fair value that you can revisit over time as new information about the business becomes available.
Community views on Centene sit far apart, with one side leaning into margin recovery and the other focused on policy and contract risk.
Bull case: 20% undervalued
"Ongoing digital transformation and AI-driven payment integrity initiatives are set to deliver structural cost reductions and superior medical loss ratio management..."
Read the full Bull Case to see why Centene could be undervalued
Bear case: 48% overvalued
"Rising government scrutiny over managed care costs and ongoing legislative focus on pricing transparency are set to intensify regulatory pressure on Centene..."
Read the full Bear Case to see why Centene could be overvalued
Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!
The Bottom Line
Centene still screens as undervalued on market multiples, even after a strong 1 year return. The market appears to be pricing in cautious expectations relative to sector norms and the model fair ratios referenced earlier. The key question is whether Centene can deliver on margin recovery and maintain its improved outlook without a meaningful reset in sentiment around policy and contract risk. That tension between earnings quality and regulatory overhang will likely determine whether the current discount becomes an opportunity or proves to be a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com